Companies

KYMR · Biotech

Kymera Therapeutics, Inc.

SEC company filings

Reported cash

USD 373,374,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · Clinical readout window

BROADEN2 · By year-end 2026

moderate to severe AD

Phase 2b

NCT07217015

Announced Oct 29, 2026 · Announced window

Official announcement
Source wording

In October 2026, the last patient received their final dose and completed the week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with moderate to severe AD. The Company plans to report topline data by year-end 2026. Subject to discussions with regulators, the Company expects to initiate the first Phase 3 trial in AD by mid-2027.

Clinical readout window

BREADTH · late 2027

moderate to severe eosinophilic asthma

Phase 2b

Announced Oct 29, 2026 · Announced window

Official announcement
Source wording

Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027.

Drug pipeline

6 programs · 11 verified studies

KT-253

Phase

Phase1

Study status

Completed
View details

Kymera Therapeutics, Inc.

IndicationMyeloid Malignancies; Acute Lymphocytic Leukemia; Lymphomas; Advanced Solid Tumors

Actual study completion2024-12-18

KT-333

Phase

Phase1

Study status

Completed
View details

Kymera Therapeutics, Inc.

IndicationNon Hodgkin Lymphoma (NHL); Peripheral T-cell Lymphoma (PTCL); Cutaneous T-Cell Lymphoma (CTCL); Large Granular Lymphocytic Leukemia (LGL-L); T-cell Prolymphocytic Leukemia (T-PLL); Solid Tumors

Actual study completion2025-03-03

KT-413

Phase

Phase1

Study status

Completed
View details

Kymera Therapeutics, Inc.

IndicationNon Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; DLBCL; MYD88 Gene Mutation

Actual study completion2023-07-28

KT-474

Phase

Phase1

Study status

Completed
View details

Kymera Therapeutics, Inc.

IndicationHealthy Volunteer; Atopic Dermatitis; Hidradenitis Suppurativa

Actual study completion2022-10-20

KT-579

Phase

Phase1

Study status

Completed
View details

Kymera Therapeutics, Inc.

IndicationHealthy Participants

Actual study completion2026-08-22

KT-621

Phase

Phase1

Study status

Completed
View details

Kymera Therapeutics, Inc.

IndicationHealthy Participants Study

Actual study completion2025-04-23

KT-621

Phase

Phase1

Study status

Completed
View details

Kymera Therapeutics, Inc.

IndicationAtopic Dermatitis

Actual study completion2025-11-10

KT-621

Phase

Phase2

Study status

Active not recruiting
View details

Kymera Therapeutics, Inc.

IndicationAtopic Dermatitis

Estimated study completion2028-06

Announced catalyst timingBy year-end 2026

KT-621

Phase

Phase2

Study status

Recruiting
View details

Kymera Therapeutics, Inc.

IndicationEosinophilic Asthma

Estimated study completion2027-12

KT-621

Phase

Phase2

Study status

Recruiting
View details

Kymera Therapeutics, Inc.

IndicationAsthma (Diagnosis)

Estimated study completion2028-12

1 / 2

3 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.